Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer
China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has secured a pivotal regulatory milestone:...
Company
Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced the nationwide launch of...
Fosun Secures FDA Approval for Two Denosumab Biosimilar Formulations
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that the Biologics License...
Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the U.S. Food and Drug Administration...
Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China
Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced the commercial launch of Tapcom (tafluprost/timolol maleate) in...
ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149) and Hayoo Biotech have...
Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of Sino Biopharmaceutical Ltd...
Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its inebilizumab injection has received...
Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia
Eli Lilly (NYSE: LLY) China has announced a strategic partnership with JD Health (HKG: 6618)...
Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone
US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its oral primary biliary cholangitis (PBC) treatment,...
Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402
Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...
JCBio & MGI Launch Korea’s First DCS Lab to Accelerate Multi‑Omics Innovation
South Korean biotechnology firm JCBio and global genomics leader MGI Tech Co., Ltd. today signed...
IVD Medical Acquires 20 % of GoFintech in HK$3.14 B Deal
IVD Medical Holding Limited (HKG: 1931) disclosed that it will purchase 1,848,496,429 shares of GoFintech...
Fosun Pharma Secures China Rights to Accropeutics’ AC‑201 JAK Inhibitor
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that it has...
Shenlian Bio Launches Phase 2 Trial for UB‑221 Injection in Chronic Urticaria
Shanghai Shenlian Biomedical Co., Ltd. (Shenlian Bio, SHA: 688098) announced that its licensed innovative drug,...
Mabwell’s 9MW3811 Receives NMPA Phase II Approval for Pathological Scar Treatment
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced on September 1 that the National Medical...
Suzhou Zelgen Secures FDA Approval for Dual‑Targeted Therapy Trial in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the U.S. Food and Drug Administration...
Mabwell Secures First Overseas Approval for Denosumab Biosimilars in Pakistan
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the Drug Regulatory Authority of Pakistan...
Novo Nordisk’s STEER Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) presented compelling real‑world evidence from the STEER...
Eisai & Biogen Secure FDA Approval for Lecanemab Auto‑Injector – Home‑Based Alzheimer’s Therapy
Japan-based Eisai (TYO: 4523) and US-based Biogen (NASDAQ: BIIB) announced that the U.S. Food and...